1997
DOI: 10.1038/sj.bjp.0700985
|View full text |Cite
|
Sign up to set email alerts
|

Inhibition of [3H]‐U69593 binding and the cardiac effects of U50,488H by calcium channel blockers in the rat heart

Abstract: The calcium channel blockers (CCBs), nifedipine, nicardipine, diltiazem and verapamil, were used to displace the binding of [3H]‐U69593 ((5a,7a,8b)‐(+)‐N‐methyl‐N‐(7‐[1‐pyrrolidinyl]‐1‐oxaspiro[4,5]dec‐8‐yl)‐benzeneacetamide), a specific κ‐opioid agonist, in the rat cardiac sarcolemma. The CCBs competed with the binding of [3H]‐U69593 (4 nm) in a dose‐dependent manner. The displacing potency of verapamil was 55 times greater than that of nifedipine. The effects of two CCBs, verapamil and nifedipine, on the arr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
4
0

Year Published

1998
1998
2008
2008

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 11 publications
(4 citation statements)
references
References 45 publications
0
4
0
Order By: Relevance
“…Nor‐BNI was purchased from Tocris Cookson Ltd. (UK). The dose range of U50,488H used in the present study was 2.5–40 μM as the agonist at this dose range increased [Ca 2+ ] i and IP 3 , as well as suppressing cyclic AMP, and the effects were antagonized by nor‐BNI at the range of 1–5 μM (Sheng et al , 1997; Zhang et al , 1997; Zhang & Wong, 1998), which itself had no effect on any of the preparation studied. The concentrations of the PKC agonist and antagonists used were based on previous studies [PMA (Capogrossi et al , 1990; Schluter, 1995), staurosporine (Ventura et al , 1991) and chelerythrine (Kandasamy et al , 1995)].…”
Section: Methodsmentioning
confidence: 69%
“…Nor‐BNI was purchased from Tocris Cookson Ltd. (UK). The dose range of U50,488H used in the present study was 2.5–40 μM as the agonist at this dose range increased [Ca 2+ ] i and IP 3 , as well as suppressing cyclic AMP, and the effects were antagonized by nor‐BNI at the range of 1–5 μM (Sheng et al , 1997; Zhang et al , 1997; Zhang & Wong, 1998), which itself had no effect on any of the preparation studied. The concentrations of the PKC agonist and antagonists used were based on previous studies [PMA (Capogrossi et al , 1990; Schluter, 1995), staurosporine (Ventura et al , 1991) and chelerythrine (Kandasamy et al , 1995)].…”
Section: Methodsmentioning
confidence: 69%
“…i transient was determined by a spectrof luorometric method described previously [18,19]. Isolated ventricular myocytes were incubated with fura-2/AM at a concentration of 4 µM in a Joklik solution supplemented with 1.25 mM CaCl 2 for 25 min.…”
Section: Methodsmentioning
confidence: 99%
“…In experiments conducted during extracellular acidosis the -opioid agonist was administered for 10 min after the perfusion of a solution at pH e 6.8 for 10 min because we also found that the effect of acidosis reached the maximum at ϳ10 min. The dose range used in the present study has been shown to increase the [Ca 2ϩ ] i and inositol 1,4,5-trisphosphate level, effects antagonized by 1-5 mM nor-BNI (51,54,55), which itself had no effect on any of the preparations studied. In a preliminary experiment, 10 µM EIPA did not alter the autofluorescence of the cell at the BCECF excitation wavelength as previously reported (29).…”
Section: Methodsmentioning
confidence: 59%
“…Both -opioid receptors (27,44,45,53,54) and -opioid peptides (48) are present in the heart. Previous studies have shown that during myocardial ischemia the -opioid receptor is activated presumably because of an increased release of -opioid peptides from the heart (50,51).…”
mentioning
confidence: 99%